Seng lai tan (13 Ergebnisse)

Hardcover. Zustand: As New. First Edition. Superior copy, gift-quality condition, inside and out, no discernible wear, bright and shiny dust jacket, straight outta the publisher's packing box. Contributions by the two editors, Seng-Lai Tan and Yupeng He, and by, among others, Atul Agarwal, Stuart Cockerill, Craig A. Belon, Milind Deshpande, Brad O. Buckman, Heidi E. Drummer, Zhaohui Cai, Menashe Elazar, Kevin X. Chen. Double-column texts for ease of reading and replete with illustrations and photographs galore. x [2], 4-389 pp., and with notes, bibliography and full index, followed by a range of full-color, full-page plates, printed on high-gloss paper.Member, I.O.B.A., C.B.A., and adherent to the highest ethical standards. Additional postage may be required for oversize or especially heavy volumes, and for sets.…

Hardcover. Zustand: Brand New. 1st edition. 370 pages. 10.00x8.00x1.00 inches. In Stock.

Zustand: New. In English.

Zustand: New.

Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 314 | Sprache: Englisch | Produktart: Bücher | Keine Beschreibung verfügbar.

Taschenbuch. Zustand: Neu. Immuno-Oncology | Cellular and Translational Approaches | Seng-Lai Tan | Taschenbuch | Methods in Pharmacology and Toxicology | x | Englisch | 2021 | Springer | EAN 9781071601730 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.…

Zustand: New. Seng-Lai Tan, PhD, is Chief Scientific Officer at Immunitas Therapeutics. He has more than 20 years of drug discovery and development experience in both small and large molecule therapeutic modalities, including multi-specific antibodies and stapled peptide.

Zustand: New.

Hardcover. Zustand: Brand New. 1st edition. 297 pages. 9.00x6.00x1.00 inches. In Stock.

Zustand: New. In English.

Gebunden. Zustand: New. KlappentextrnrnThe hepatitis C virus (HCV) is a significant public health problem of international importance. HCV is capable of establishing chronic infections resulting in progressive liver damage and other problems. Current drug therapies are.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book serves as a guide for identifying and applying commonly used cell-based translational assays as well as for assessing the therapeutic potential of new immuno-oncology therapeutics and advancing their mechanism of action. The detailed chapters within will provide readers with a baseline understanding of the pros and cons as well as key considerations for applying assays that are more reflective of the human immune-tumor microenvironment in order to increase their translatability into the clinic. Written for the Methods in Pharmacology and Toxicology series, the contents of this volume include the kind of specifics and real-world implementation advice to ensure success in the lab. Authoritative and practical, Immuno-Oncology: Cellular and Translational Approaches aims to aid researchers working on biotechnology and pharmaceutical efforts to search for the next generation of safer and more effective cancer immunotherapeutics.…

Buch. Zustand: Neu. Neuware - The hepatitis C virus (HCV) is a significant public health problem of international importance. HCV is capable of establishing chronic infections resulting in progressive liver damage and other problems. Current drug therapies are ineffective, highlighting the need for better antiviral drugs. Recent research in HCV genetics and molecular biology have led to significant advances in our understanding of the life cycle of this important pathogen and may ultimately lead to better antiviral strategies. The editors of this book have recruited experts from around the world to produce a timely and well-compiled review of current HCV research, with an emphasis on antiviral drug development. The chapters provide in-depth reviews of the most critical areas of research. Topics include: the HCV life cycle \* HCV assays \* HCV resources \* HCV databases \* HCV infection systems \* models of hepatitis C infections \* overview of the drug pipeline \* clinical trial design \* clinical virology and drug development \* NS3 protease inhibitors \* NS3-NS4A complex inhibitors \* NS3 helicase inhibitors \* NS4B targets and inhibitors \* NS5A inhibitors \* nucleoside inhibitors \* NS5B polymerase inhibitors \* glycoprotein-dependent entry \* host cell targets and inhibitors \* innate immunity for HCV antiviral therapy.…